



SKULDTECH


**Pharmacogenomic services for
clinical trials and drug development**

info@skuldtech.com



SKULDTECH

**Biomarker benefits for
clinical trials &
drug development**



Source: Quintiles Transnational, 2004


Advantage of patient stratification within clinical trials:

The identification of new predictive safety and efficacy biomarkers reduces the time and cost of drug development by using biomarkers that can accurately identify patients who are likely to respond to the new therapy.

Genomic biomarkers: a worthwhile approach

!!! New !!! FDA guidance for industry (February 2011)

Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies





SKULDTECH

Core business & Expertise



- Corporate

- French company (Montpellier, France) established in 1999.




- Expertise

- ↪ Discovering key biological information (**biomarkers**), that is **specific** to a given disease or a physiopathological condition.
- ↪ Developing new diagnostic tools (“**companion**” diagnostics, patient **stratification** tests) in personalized medicine.
- ↪ Discovering biomarkers to **enhance** drug development process.

- Networks: local and international

- ☞ Partner of **R&D programs granted by European Union, Oseo...**
- ☞ Member of southern French bioclusters (*Biomeridies, Canceropole GSO, Eurobiomed and its diagnosis group Euromediag*).



Based on proprietary bioinformatic & biostatistical tools associated with Next Generation Sequencing / RT-PCR technologies


SERVICES

Genomics, pharmacogenomics, transcriptomics, gene profiling, sequencing...

PRODUCTS

Companion diagnostics
Patient stratification tests

Scientific & technological workflow






SKULDTECH

Background & Examples




Skuldtech investigates biomarkers at every step of the drug discovery process





■ Results

- Transcriptomic biomarkers associated with a new canine vaccine
- Study of validated biomarkers onto other canine vaccines






■ Prospects

- Developing molecular tools to new vaccine releases
- Drawing new strategies in human vaccine development



Diagnostic phase II: first molecular prognosis index

- First results in diagnosis
 - Patented transcriptomic/genomic biomarkers associated with 4-year survival
- Objective
 - Develop a molecular diagnosis to stratify patients in the next 3-4 years





SKULDTECH

**Advantages & adding value
of Skuldtech's expertise**

Skuldtech has acquired expertise and developed tools serving the needs of pharmaceutical and biotechnology companies with respect to clinical pharmacogenomics:

- Over 12 years experience in genomics/pharmacogenomics (transcriptomics, gene profiling, sequencing, SAGE/DGE method, RT-PCR...)
- Recognized by leaders in genomics/diagnosis
- Expertise in clinical pharmacology
- Cutting-edge bioinformatic tools
- Biostatistical data integration

Skuldtech adds value at every stage of the drug development pipeline

Biomarker **identification** will help to:

- Save **cost** during **clinical trials**
 - Identify drug **efficiency** and **side-effects** at **early stage**
 - Increase **enrichment** of **patient responder population**
- Decrease **time-to-market**
- Enhance **Health Authority approval** - Meeting **FDA/EMA recommendations**



SERVICES DIAGNOSTIC CORPORATE INVESTORS CONTACT



Over 12 years experience in biomarkers discovery



SERVICES
Expertise in genomics and transcriptomics



DIAGNOSTIC
Genomics for Innovative Diagnostics Solutions



CORPORATE
Innovative biotechnology company



INVESTORS
Combining personalized medicine with high profitability

SKULDTECH AT A GLANCE

Skuldtech is specialized in the discovery of Biomarkers and the development of Diagnostics focused on personalized medicine applications. This expertise enables the company to provide genomic, pharmacogenomic and transcriptomic services, as well as innovative diagnostics associated with new therapeutics especially in cancer, rare diseases and infectious diseases.

LATEST NEWS AND PRESS REVIEW

Les Echos - Skuldtech axe son développement sur la médecine personnalisée
Eco Infos n°22: "Skuldtech ou la fin de l'ère du traitement de masse"
Biofutur n°283: "Les biomarqueurs apportent des informations clés dans le domaine de la santé"
Skuldtech will attend the RARE 2011 conference (2-4 nov. 2011)
Recent news

TAG CLOUD

expression services gene
biomarker tool biology
analysis biological molecular
genomic bioinformatic
data

Skuldtech

- ☞ Tel: +33 (0)467 419 748
- ☞ Email: info@skuldtech.com
- ☞ Web: www.skuldtech.com

Contact

- ☞ D.Ritter (CEO)
- ☞ D.Piquemal (CSO)
- ☞ P.Outrebon (CFO)